当前位置: 首页 >> 检索结果
共有 1652 条符合本次的查询结果, 用时 6.9985102 秒

661. vCJD and the gut: implications for endoscopy.

作者: M W Head.;J W Ironside.
来源: Gut. 2007年56卷1期9-11页
Surveillance for infection by endoscopy for variant CJD and other human prion diseases

662. Inflammatory bowel disease: is it really just another break in the wall?

作者: C R Weber.;J R Turner.
来源: Gut. 2007年56卷1期6-8页
Although the critical factors necessary for IBD pathogenesis remain mysterious, interest in the potential role of defective epithelial barrier function continues to grow. New insight into the mechanisms responsible for barrier dysfunction in IBD may lead to understanding its contribution to disease development and progression.

663. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

作者: P Malfertheiner.;F Megraud.;C O'Morain.;F Bazzoli.;E El-Omar.;D Graham.;R Hunt.;T Rokkas.;N Vakil.;E J Kuipers.
来源: Gut. 2007年56卷6期772-81页
Guidelines on the management of Helicobacter pylori, which cover indications for management and treatment strategies, were produced in 2000.

664. Portal hypertensive biliopathy.

作者: Radha K Dhiman.;Arunanshu Behera.;Yogesh K Chawla.;Jang B Dilawari.;Sudha Suri.
来源: Gut. 2007年56卷7期1001-8页

665. Bone marrow stem cells and liver disease.

作者: Y N Kallis.;M R Alison.;S J Forbes.
来源: Gut. 2007年56卷5期716-24页

666. Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma.

作者: R C Fitzgerald.
来源: Gut. 2006年55卷12期1810-20页

667. Genes and environment in irritable bowel syndrome: one step forward.

作者: N J Talley.
来源: Gut. 2006年55卷12期1694-6页
Both low birth weight and genetic factors may be integral to the aetiological pathway in irritable bowel syndrome

668. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease.

作者: I N Guha.;J Parkes.;P R Roderick.;S Harris.;W M Rosenberg.
来源: Gut. 2006年55卷11期1650-60页
The diagnosis of fibrosis within liver disease is important for prognosis, stratification for treatment, and monitoring of treatment efficacy. The rising incidence and prevalence of non-alcoholic fatty liver disease (NAFLD) has driven the search for accurate non-invasive tools of liver fibrosis within this condition. With the aid of a systematic review, we explore how the field has evolved from the discovery of simple blood parameters to panel markers of liver fibrosis. We will discuss the biological plausibility, limitations, potential uses, and emerging diagnostic techniques of non-invasive markers in this rapidly expanding field.

669. The role of the sympathetic nervous system in intestinal inflammation.

作者: R H Straub.;R Wiest.;U G Strauch.;P Härle.;J Schölmerich.
来源: Gut. 2006年55卷11期1640-9页
The nervous system in the intestine controls motility, secretion, sensory perception, and immune function. Peptidergic neurones with neurotransmitters such as substance P and nerve growth factors have been the main focus of neuroimmunomodulation research in the gut. This review summarises the present knowledge concerning the role of the sympathetic nervous system (SNS) in modulating intestinal inflammation. The role of the SNS for gut inflammation is compared with its role in rheumatoid arthritis which demonstrates notable similarities. Nerve fibres of the SNS not only enter the enteric plexuses but also innervate the mucosa and gut associated lymphoid tissue (GALT). The SNS has pro- and anti-inflammatory functions. Neurotransmitters such as norepinephrine, adenosine, and others can evoke remarkably different opposing effects depending on concentration (presence of sympathetic nerve fibres and extent of neurotransmitter release), receptor affinity at different receptor subtypes, expression of adrenoceptors, availability of cotransmitters, and timing of SNS activity in relation to the inflammatory course. This review attempts to integrate the different perspectives of the pro- and anti-inflammatory effects of the SNS on inflammatory disease of the gut.

670. Altered monoaminergic transporter binding in hepatitis C related cerebral dysfunction: a neuroimmunologial condition?

作者: D M Forton.
来源: Gut. 2006年55卷11期1535-7页
There may be a role for disturbed monoaminergic neurotransmission in the pathophysiology of hepatitis C virus associated cerebral dysfunction

671. An unfavourable prognosis for pancreatic cancer indicates fields of opportunity.

作者: W Greenhalf.
来源: Gut. 2006年55卷11期1533-5页
Large fields of cancerisation may give more aggressive, but easier to detect, pancreatic ductal adenocarcinoma

672. Acid inhibitory medication and risk of gastric and oesophageal cancer.

作者: K E L McColl.
来源: Gut. 2006年55卷11期1532-3页
What are the long term effects of acid suppressive medication on the risk of gastric and oesophageal cancer?

673. Liver transplantation alcohol related liver disease: (deliberately) stirring a hornet's nest!

作者: J G O'Grady.
来源: Gut. 2006年55卷11期1529-31页
Outcomes after liver transplantation for alcohol related liver disease compare very favourably with those documented for other causes of cirrhosis. Despite this, 5% or less of patients with advanced alcohol related liver disease are considered for transplantation. The reasons for this are complex but include professional reluctance to refer these patients for formal assessment as well as a limited and dwindling number of organs available for transplantation. Demonstrating abstinence from alcohol consumption remains central to the assessment of candidates for transplantation. Return to alcohol consumption after transplantation can follow a pattern of abuse with consequences for health and survival but may also be controlled and of little clinical significance. A better understanding of the issues influencing these outcomes should decrease the tension that currently exists between patient expectations, professional opinion, and the attitude of the general public who gift organs for donation.

674. Treatment for painful calcified chronic pancreatitis: extracorporeal shock wave lithotripsy versus endoscopic treatment: a randomised controlled trial.

作者: Jean-Marc Dumonceau.;Guido Costamagna.;Andrea Tringali.;Kouroche Vahedi.;Myriam Delhaye.;Axel Hittelet.;Gianluca Spera.;Emiliano Giostra.;Massimiliano Mutignani.;Viviane De Maertelaer.;Jacques Devière.
来源: Gut. 2007年56卷4期545-52页
In chronic pancreatitis, obstruction of the main pancreatic duct (MPD) may contribute to the pathogenesis of pain. Pilot studies suggest that extracorporeal shock wave lithotripsy (ESWL) alone relieves pain in calcified chronic pancreatitis.

675. Immunopathogenesis of IBD: insufficient suppressor function in the gut?

作者: I L Huibregtse.;A U van Lent.;S J H van Deventer.
来源: Gut. 2007年56卷4期584-92页

676. Guidelines on the management of ascites in cirrhosis.

作者: K P Moore.;G P Aithal.
来源: Gut. 2006年55 Suppl 6卷Suppl 6期vi1-12页

677. Alterations in intestinal permeability.

作者: M C Arrieta.;L Bistritz.;J B Meddings.
来源: Gut. 2006年55卷10期1512-20页

678. Antiangiogenic therapy in human gastrointestinal malignancies.

作者: J Heidemann.;D G Binion.;W Domschke.;T Kucharzik.
来源: Gut. 2006年55卷10期1497-511页

679. Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander?

作者: Laurent Peyrin-Biroulet.;Mathias Chamaillard.;Florent Gonzalez.;Elodie Beclin.;Cecilia Decourcelle.;Laurent Antunes.;Jérôme Gay.;Christel Neut.;Jean-Frédéric Colombel.;Pierre Desreumaux.
来源: Gut. 2007年56卷4期577-83页

680. Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications.

作者: J Mudter.;M F Neurath.
来源: Gut. 2007年56卷2期293-303页
共有 1652 条符合本次的查询结果, 用时 6.9985102 秒